SCHOTT Pharmaceutical Systems has unveiled plans for expanding production capacities by 20% at its facility in Bekasi, Indonesia. With ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

The UK is now the first nation to approve the maximum dose 7.2mg Wegovy regimen, which will be used to treat obesity.

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

InterAx Biotech has entered into a strategic research collaboration and licensing agreement with Alveus Therapeutics to ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...